Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
A Twice repetition of IV infusion of 0.5 mg/kg of ketamine produces an antidepressant response in individuals with treatment‐resistant MDD The work aims to: 1. To assess the onset of action and degree of improvement and the duration of antidepressant effect of ketamine in a sample of patients with treatment ‐resistant major depressive disorder. 2. To find out whether the onset of Ketamine antidepressant effect is associated with an improvement of suicidality in those patients.
Epistemonikos ID: e1e08b06b9e100020085630f7997f7977f4472be
First added on: May 22, 2024